How do we manage t(11;14) plasma cell disorders with venetoclax?

Summary The oral BCL‐2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single‐agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non‐t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case‐based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax.